Skip to main content
Log in

Doping con eritropoietina

  • Published:
L’Endocrinologo Aims and scope

Riassunto

L’eritropoietina è un ormone glicoproteico d’origine renale che regola la produzione di globuli rossi. Le eritropoietine usate nella terapia dell’anemia da insufficienza renale e nei pazienti neoplastici sono preparate con tecniche ricombinanti mediante transfezione del gene umano in cellule di mammifero. Di conseguenza le eritropoietine ricombinanti possiedono un maggior contenuto zuccherino. Quest a caratteristica le rende riconoscibili nelle urine mediante tecniche immunoelettroforetiche. Ancor meglio riconoscibile è la darbopoietina perché possiede un maggior numero di molecole d’acido sialico. Le suddette tecniche sono quindi impiegate per rivelare l’uso di eritropoietine nel doping degli atleti.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. Krantz SB. Erythropoietin. Blood 77: 419, 1991.

    CAS  PubMed  Google Scholar 

  2. D’Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86: 681, 1990.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 81: 2223, 1993.

    CAS  PubMed  Google Scholar 

  4. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ; European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62: 2167, 2002.

    Article  CAS  PubMed  Google Scholar 

  5. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083, 2002.

    Article  CAS  PubMed  Google Scholar 

  6. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 85: 561, 2000.

    CAS  PubMed  Google Scholar 

  7. Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 87: 232, 2002.

    PubMed  Google Scholar 

  8. Stanley SM, Poljak A. Matrix-assisted laser-desorption time-of flight ionisation and high-performance liquid chromatography-electrospray ionisation mass spectral analyses of two glycosylated recombinant epoetins. J Chromatogr B Analyt Technol Biomed Life Sci 785: 205, 2003.

    Article  CAS  PubMed  Google Scholar 

  9. Caldini A, Moneti G, Fanelli A, Bruschettini A, Mercurio S, Pieraccini G, Cini E, Ognibene A, Luceri F, Messeri G. Epoetin alpha, epoetin beta and darbopoetin alfa: 2-DE isoform characterisation and MS analysis. Proteomics in Press.

  10. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311: 119, 2002.

    Article  CAS  PubMed  Google Scholar 

  11. Lasne F, De Ceaurriz J. Recombinant erythropoietin in urine. Nature 405: 635, 2000.

    Article  CAS  PubMed  Google Scholar 

  12. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48: 2057, 2002.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paola Romagnani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buonamano, A., Romagnani, P. Doping con eritropoietina . L’Endocrinologo 4, 90–92 (2003). https://doi.org/10.1007/BF03344455

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344455

Navigation